O Shaughnessy Asset Management LLC Purchases 8,475 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

O Shaughnessy Asset Management LLC lifted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 11.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 80,710 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,475 shares during the quarter. O Shaughnessy Asset Management LLC owned about 0.25% of Collegium Pharmaceutical worth $2,312,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Nisa Investment Advisors LLC grew its holdings in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 316 shares during the period. AlphaQuest LLC increased its position in Collegium Pharmaceutical by 3.0% during the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock valued at $366,000 after buying an additional 374 shares in the last quarter. Gallacher Capital Management LLC raised its stake in Collegium Pharmaceutical by 3.3% during the fourth quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock valued at $417,000 after buying an additional 470 shares during the last quarter. TD Private Client Wealth LLC boosted its holdings in Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after acquiring an additional 483 shares in the last quarter. Finally, Caprock Group LLC grew its stake in shares of Collegium Pharmaceutical by 6.7% in the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company’s stock worth $249,000 after acquiring an additional 543 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on COLL shares. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Friday, January 10th. Piper Sandler dropped their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Stock Down 3.0 %

COLL opened at $28.14 on Friday. The stock has a market capitalization of $904.19 million, a price-to-earnings ratio of 12.13 and a beta of 0.76. The firm has a 50 day moving average price of $30.02 and a 200-day moving average price of $32.19. Collegium Pharmaceutical, Inc. has a twelve month low of $27.28 and a twelve month high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Scott Dreyer sold 2,255 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the sale, the executive vice president now owns 124,421 shares of the company’s stock, valued at $3,732,630. This trade represents a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is owned by company insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.